Clinical Aspects of Chronic Use of Alprazolam and Lorazepam
Overview
Authors
Affiliations
Objective: The authors' goal was to determine the clinical characteristics of persistent users of alprazolam or lorazepam who wished to discontinue their medication.
Method: Long-term users (daily use for more than 3 months) of alprazolam (N = 34) or lorazepam (N = 97) who entered an outpatient treatment program for discontinuation of benzodiazepines were carefully assessed. Detailed histories of benzodiazepine use were obtained; a structured interview was used to make psychiatric diagnoses based on DSM-III-R criteria.
Results: The majority of patients were using low therapeutic doses of medication (lorazepam: mean = 2.7 mg/day; alprazolam: mean = 1.2 mg/day) and had either maintained their initial daily dose over time or decreased it. Individuals tended to shift their use of medication from an as-prescribed to an as-needed pattern. Forty-seven percent of the patients were diagnosed with at least one current anxiety disorder, most commonly generalized anxiety. At least one diagnosable personality disorder was found in 45% of the patients, most commonly obsessive-compulsive personality disorder. Patterns of benzodiazepine use were influenced by age, gender, and past history of alcohol dependence.
Conclusions: Long-term users of alprazolam/lorazepam seeking treatment for discontinuation had clinically important past and current psychiatric histories. They used a constant or decreasing dose of medication and made attempts to stop their use. Persistent use of alprazolam/lorazepam for therapeutic purposes did not represent abuse or addiction as the terms are usually understood. A substantial proportion of these patients may be receiving appropriate maintenance therapy for a chronic psychiatric condition.
Deppe M, Abdelnaim M, Hebel T, Kreuzer P, Poeppl T, Langguth B Eur Arch Psychiatry Clin Neurosci. 2020; 271(1):61-67.
PMID: 32648109 PMC: 7867521. DOI: 10.1007/s00406-020-01160-9.
Olesiejuk M, Kudelko A, Swiatkowski M, Kruszynski R Molecules. 2019; 24(3).
PMID: 30759857 PMC: 6384732. DOI: 10.3390/molecules24030652.
Clonazepam as agonist substitution treatment for benzodiazepine dependence: a case report.
Maremmani A, Rovai L, Rugani F, Bacciardi S, Pacini M, DellOsso L Case Rep Psychiatry. 2013; 2013:367594.
PMID: 23424702 PMC: 3570932. DOI: 10.1155/2013/367594.
Becker W, Fiellin D, Desai R Drug Alcohol Depend. 2007; 90(2-3):280-7.
PMID: 17544227 PMC: 3745028. DOI: 10.1016/j.drugalcdep.2007.04.009.
Vasile R, Bruce S, Goisman R, Pagano M, Keller M Depress Anxiety. 2005; 22(2):59-67.
PMID: 16094662 PMC: 3272770. DOI: 10.1002/da.20089.